Literature DB >> 31757394

Whole body FDG-PET/CT for the assessment of bone marrow infiltration in patients with newly diagnosed lymphoma.

Wang Xiao-Xue1, Huang Xinyue1, Zhang Lijun2.   

Abstract

BACKGROUND: Positron emission tomography-computed tomography (PET-CT) and bone marrow biopsy are currently the common clinical examination of lymphoma infiltration. The aim of this research is to evaluate the value of PET-CT in diagnosis of bone marrow infiltration, clinical staging and pathological typing of lymphoma.
METHODS: 153 cases were analyzed retrospectively to compare the consistency of PET-CT and bone marrow biopsy. We analyzed the sensitivity, accuracy and specificity of PET-CT in different clinical pathology of lymphoma.
RESULTS: The PET-CT sensitivity in detecting bone marrow infiltration is 54.3% with a specificity of 80.5% and accuracy of 74.5%. In aggressive B-cell lymphoma (DLBCL, HG-BL) and MZL, PET-CT results of bone marrow infiltration showed high accuracy of 88.1% and 83.3% respectively. The median value of SUVmax in the patients detected to have bone marrow infiltration by BMB was significantly higher than patients with BMB negative results among subgroups of aggressive B-cell lymphoma, MZL and T-NHL (p<.05).
CONCLUSION: PET-CT is significant in detecting bone marrow infiltration in certain pathological types of lymphoma. However pathological inconsistencies still exist between bone marrow biopsy and PET-CT, thus PET-CT cannot completely replace biopsy.
Copyright © 2019 The Authors. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Ann Arbor stage; Bone marrow infiltration; Estadificación de Ann Arbor; Infiltración de la médula ósea; Linfoma; Lymphoma; PET/TC; PET–CT; SUVmax; SUVmáx

Year:  2019        PMID: 31757394     DOI: 10.1016/j.medcli.2019.07.022

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  5 in total

1.  Utility of 18F-fluorodeoxyglucose PET-CT scan in detecting bone marrow involvement in lymphoma.

Authors:  Ankit Kumar Jitani; Shyamali Dutta; Prakas Kumar Mandal; Rajib De; Ekta Jajodia; Shuvraneel Baul; Prantar Chakrabarti; Tuphan Kanti Dolai
Journal:  Indian J Med Res       Date:  2021-05       Impact factor: 5.274

2.  Dual-Energy Computed Tomography-Based Quantitative Bone Marrow Imaging in Non-Hematooncological Subjects: Associations with Age, Gender and Other Variables.

Authors:  Florian Hagen; Jan Fritz; Antonia Mair; Marius Horger; Malte N Bongers
Journal:  J Clin Med       Date:  2022-07-14       Impact factor: 4.964

3.  Detecting marrow involvement in lymphoma: Can-18F fluorodeoxyglucose positron emission tomography elude the need for biopsy?

Authors:  Prateek Kaushik; Madhavi Tripathi
Journal:  Indian J Med Res       Date:  2021-05       Impact factor: 5.274

4.  Whole-body [18F]-FDG-PET/MRI for staging of pediatric non-Hodgkin lymphoma: first results from a single-center evaluation.

Authors:  L Kurch; R Kluge; O Sabri; L Fischer; S Wendt; H Graf Einsiedel; S Starke; J-S Kühl; H Christiansen; F W Hirsch; I Sorge; C Roth
Journal:  EJNMMI Res       Date:  2021-07-03       Impact factor: 3.138

5.  The value of bone marrow biopsy for staging of patients with primary CNS lymphoma.

Authors:  Michelle Margold; Sabine Seidel; Thomas Kowalski; Swetlana Ladigan-Badura; Alexander Baraniskin; Roland Schroers; Anna Verena Frey; Ingo G H Schmidt-Wolf; Ulrich Herrlinger; Agnieszka Korfel; Uwe Schlegel
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 12.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.